The company's pharmaceutical platform focuses on small molecules that target novel bacterial strains, addressing the need for new treatments against life-threatening infections. Bioversys uses its TRIC technology to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria. Their research and development programs address nosocomial infections of Acinetobacter baumannii and tuberculosis, in collaboration with GlaxoSmithKline and the University of Lille. Bioversys is located in the Technologiepark in Basel, Switzerland.